Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

Abstract

Resistance of tumors to treatment with cytotoxic drugs, irradiation or immunotherapy may be due to disrupted apoptosis programs. Here, we report in a variety of different tumor cells including Ewing tumor, neuroblastoma, malignant brain tumors and melanoma that caspase-8 expression acts as a key determinant of sensitivity for apoptosis induced by death-inducing ligands or cytotoxic drugs. In tumor cell lines resistant to TRAIL, anti-CD95 or TNFα, caspase-8 protein and mRNA expression was decreased or absent without caspase-8 gene loss. Methylation-specific PCR revealed hypermethylation of caspase-8 regulatory sequences in cells with impaired caspase-8 expression. Treatment with the demethylation agent 5-Aza-2′-deoxycytidine (5-dAzaC) reversed hypermethylation of caspase-8 resulting in restoration of caspase-8 expression and recruitment and activation of caspase-8 at the CD95 DISC upon receptor cross-linking thereby sensitizing for death receptor-, and importantly, also for drug-induced apoptosis. Inhibition of caspase-8 activity also inhibited apoptosis sensitization by 5-dAzaC. Similar to demethylation, introduction of caspase-8 by gene transfer sensitized for apoptosis induction. Hypermethylation of caspase-8 was linked to reduced caspase-8 expression in different tumor cell lines in vitro and, most importantly, also in primary tumor samples. Thus, these findings indicate that re-expression of caspase-8, e.g. by demethylation or caspase-8 gene transfer, might be an effective strategy to restore sensitivity for chemotherapy- or death receptor-induced apoptosis in various tumors in vivo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Anderson J, Gordon A, Pritchard-Jones K, Shipley J . 1999 Genes Chromosomes Cancer 2: 275–285

  • Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J . 2000 Nat. Cell. Biol. 2: 241–243

  • Chinnaiyan AM, Teppert CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Peter ME, Dixit VM . 1996 J. Biol. Chem. 271: 4961–4965

  • Debatin KM . 1997 J. Natl. Cancer Inst. 89: 750–751

  • Deveraux QL, Reed JC . 1999 Genes Dev. 13: 239–252

  • De Vita VT . 1990 J. Natl. Cancer Inst. Monogr. 10: 19–28

  • Fernandes-Alnemri T, Armstrong RC, Krebs J, Srinivasula SM, Wang L, Bullrich F, Fritz LC, Trapani JA, Tomaselli KJ, Litwack G, Alnemri ES . 1996 Proc. Natl. Acad. Sci. USA 93: 7464–7469

  • Friesen C, Herr I, Krammer PH, Debatin KM . 1996 Nat. Med. 2: 574–577

  • Friesen C, Fulda S, Debatin KM . 1997 Leukemia 11: 1833–1841

  • Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM . 1997 Cancer Res. 57: 3823–3829

  • Fulda S, Susin SA, Kroemer G, Debatin KM . 1998a Cancer Res. 58: 4453–4460

  • Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM . 1998b Cell Death Differ. 5: 884–893

  • Fulda S, Meyer E, Debatin KM . 2000 Cancer Res. 60: 3947–3956

  • Fulda S, Meyer E, Susin SA, Kroemer G, Debatin KM . 2001 Oncogene in press

  • Grenet J, Teitz T, Wei T, Valentine V, Kidd VJ . 1999 Gene 226: 225–232

  • Griffith TS, Lynch DH . 1998 Curr. Opinion Immunol. 10: 559–563

  • Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM, Phillips PC . 2000 Oncogene 19: 4604–4610

  • Hendrich B, Bird A . 2000 Curr. Top. Microbiol. Immunol. 249: 55–74

  • Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826

  • Herman JG, Baylin SB . 2000 Curr. Top. Microbiol. Immunol. 249: 35–54

  • Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N . 2000 Cancer Res. 60: 4315–4319

  • Jones PA . 1985 Cell 40: 485–486

  • Juo P, Kuo CJ, Yuan J, Blenis, J . 1998 Curr. Biol. 8: 1001–1008

  • Kaufmann SH, Earnshaw WC . 2000 Exp. Cell Res. 256: 42–49

  • Kischkel FC, Hellbrandt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME . 1995 EMBO J. 4: 5579–5588

  • Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A . 2000 Immunity 12: 611–620

  • Kroemer G . 1997 Nat. Med. 3: 614–620

  • Kroemer G, Reed JC . 2000 Nat. Med. 6: 513–519

  • Li H, Zhu H, Xu CJ, Yuan J . 1998 Cell 94: 491–501

  • Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM . 1997 Blood 90: 3118–3129

  • Mandruzzato SF, Andry G, Boon T, van der Bruggen P . 1997 J. Exp. Med. 186: 785–793

  • Maris JM, Matthay KK . 1999 J. Clin. Oncol. 17: 2264–2279

  • Medema JP, Scaffidi C, Kischkel FC, Shevchenko ANJ, Mann M, Krammer PH, Peter ME . 1997 EMBO J. 16: 2794–2804

  • Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko ANJ, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM . 1996 Cell 85: 817–827

  • Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . 1991 J. Immunol. Methods 139: 271–279

  • Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, Ponstingl H, Krammer PH . 1992 J. Biol. Chem. 267: 10709–10715

  • Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM . 1999 J. Exp. Med. 190: 1679–1688

  • Peter ME, Krammer PH . 1998 Curr. Opinion Immunol. 10: 545–551

  • Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales F, Jones PA . 1999 Nucleic Acids Res. 27: 2291–2298

  • Scaffidi C, Medema JP, Krammer PH, Peter ME . 1997 J. Biol. Chem. 272: 26953–26958

  • Scaffidi C, Fulda S, Li F, Friesen C, Srinivasan A, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME . 1998 EMBO J. 17: 1675–1687

  • Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H . 2000 Immunity 12: 599–609

  • Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G . 1999a Nature 397: 441–446

  • Susin SA, Lorenzo HK, Zamzami N, Marzo I, Brenner C, Larochette N, Prevost MC, Alzari PM, Kroemer G . 1999b J. Exp. Med. 189: 381–394

  • Tang D, Lahti JM, Kidd VJ . 2000 J. Biol. Chem. 275: 9303–9307

  • Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ . 2000 Nat. Med. 6: 529–535

  • Thornberry N, Lazebnik Y . 1998 Science 281: 1312–1316

  • Trauth BC, Klas C, Peter AMJ, Matz S, Möller P, Falk W, Debatin KM, Krammer PH . 1989 Science 245: 301–305

  • Tschopp J, Irmler M, Thome M . 1998 Curr. Opin. Immunol. 10: 552–558

  • Tycko B . 2000 J. Clin. Invest. 105: 401–407

  • van Valen F . 1999 Ewing's sarcoma family of tumors Masters JRW and Palsson B (eds) Kluwer Academic Publishers: Great Britain pp. 55–85

    Google Scholar 

  • van Valen F, Fulda S, Truckenbrod B, Eckervogt V, Sonnemann J, Hillmann A, Roedl R, Hoffmann C, Winkelmann W, Schäfer L, Dockhorn-Dworniczak B, Wessel T, Boos J, Debatin KM, Juergens H . 2000 Int. J. Cancer. 88: 311–319

  • Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, Lapidot T, Soffer D, Sobe T, Avraham KB, Goncharov T, Holtmann H, Lonai P, Wallach D . 1998 Immunity 9: 267–276

  • Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ . 1999 Nature 400: 886–891

  • Zou H, Li Y, Liu X, Wang X . 1999 J. Biol. Chem. 274: 11549–11556

Download references

Acknowledgements

We thank PH Krammer (DKFZ, Heidelberg, Germany) for anti-FLICE antibody, T Pietsch (University of Bonn, Bonn, Germany) for medulloblastoma tumor samples and E Alnemri (Philadelphia, PA, USA) for dominant negative caspase-8 cDNA. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Bundesministerium für Forschung und Technologie, Bonn, the Deutsche Leukämieforschungshilfe and the Wilhelm Sander-Stiftung.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Klaus-Michael Debatin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fulda, S., Küfer, M., Meyer, E. et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20, 5865–5877 (2001). https://doi.org/10.1038/sj.onc.1204750

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204750

Keywords

This article is cited by

Search

Quick links